Skip to content

BREAST

XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease

VIEW HERE

Participating Practices:

  • Highlands Oncology Group
  • Northwest Medical Specialties

COLORECTAL 

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

VIEW HERE

Participating Practices:

  • Fort Wayne Medical Oncology and Hematology
  • Nebraska Cancer Specialists
  • New Jersey Cancer Care and Blood Disorders
  • Northwest Medical Specialties
  • Oklahoma Cancer Specialists and Research Institute
  • Oregon Oncology Specialists
  • Pontchartrain Cancer Center
  • Stockton Hematology Oncology Medical Group
  • University Cancer and Blood Center
  • Virginia Cancer Institute

LUNG

A Phase II, Open-label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-doublet Chemotherapy in Patients Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-small Cell Lung Cancer

VIEW HERE

Participating Practices:

  • Highlands Oncology Group
  • University Cancer and Blood Center

Sponsors and CROs please contact Rosemary McQueary, Director of Research at rmcqueary@qcca.us.com or 317-313-6879 for study placement and information on network capabilities.